ArticleTranslational oncology2026
Circ_0008777 promotes head and neck squamous cell carcinoma progression by elevating c-Myc expression levels via interacting with PC4 and miR-185-3p.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circular RNAs (circRNAs) have emerged as key players in tumor progression, yet their role in head and neck squamous cell carcinoma (HNSCC) remains largely unexplored. The AURKA gene is frequently amplified and activated in HNSCC. This study investigates the expression patterns and functions of circ_0008777, which is derived from AURKA exons 3-6, in HNSCC. The biological functions of circ_0008777 were evaluated in vitro and in vivo, along with its interactions with positive cofactor 4 (PC4) and miR-185-3p. Our data indicated that circ_0008777 expression levels are upregulated in HNSCC tissues and cell lines, and linked to aggressive clinical features. Knocking down circ_0008777 significantly inhibited HNSCC cell proliferation and migration in vitro, as well as restrained tumor growth in vivo, while overexpressing circ_0008777 had the opposite effects. Mechanistically, circ_0008777 can bind to PC4 to increase c-Myc transcription. Bioinformatics analysis showed that PC4 is highly expressed in HNSCC patients, with survival analysis revealing a negative correlation between PC4 expression and overall survival rates. PC4 knockout could hinder HNSCC cell proliferation and migration in vitro. Additionally, circ_0008777 can bind to miR-185-3p through a microRNA sponge mechanism, relieving miR-185-3p-mediated repression of c-Myc mRNA. Furthermore, the inhibitory effects of circ_0008777 knockdown on the cell migration and proliferation rates were rescued by c-Myc overexpression. In conclusion, circ_0008777 can promote HNSCC progression by upregulating c-Myc expression through both PC4- and miR-185-3p-related mechanisms, showing potential as a candidate therapeutic target in this cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.